No change
Create an alert
Stocks and Shares ISAKyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Information
About this company
Key people
Christi Shaw
Executive Chairman of the Board
Sravan K. Emany
Independent Director
Warner Biddle
Chief Executive Officer, Director
Gregory Martini
Chief Financial Officer
Mayo Pujols
Chief Technology Officer
Naji H. Gehchan
Chief Medical and Development Officer
Andrew Craig Miller
Director
Mert Aktar
Independent Director
Ian T. Clark
Independent Director
Frederick E. Cohen
Independent Director
Click to see more
Key facts
- Shares in issue60.80m
- EPICKYTX
- ISINUS5019761049
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capGBX 0.00
- Employees129
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.